about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

De­cry­ing 'ar­bi­trary and capri­cious' ac­tion, Re­genxBio sues FDA over clin­i­cal holds on gene ther­a­py

6 years ago
Cell/Gene Tx
FDA+

Roche's SMA chal­lenge to Bio­gen's Spin­raza fran­chise looms larg­er with piv­otal win

6 years ago
R&D

Tot Bio­pharm com­pletes HKEX list­ing, rais­ing $63M in mod­est de­but

6 years ago
Financing
China

Fol­low­ing a win for Baven­cio, Pfiz­er and Mer­ck KGaA con­tin­ue PD-L1 los­ing streak

6 years ago
R&D
Pharma

Monopar de­lays IPO again de­spite slash­ing of­fer­ing while a mi­cro-cap biotech clinch­es $9M

6 years ago
Financing

New cell ther­a­py play­er launch­es with $57M from mar­quee in­vestors to go af­ter 'de­fin­i­tive' tu­mor tar­gets

6 years ago
Financing
Startups

Roche aban­dons an­ti-myo­statin ap­proach to Duchenne MD — one more nail in the class' cof­fin

6 years ago
R&D

Re­genxBio runs in­to par­tial hold for an­ti-VEGF gene ther­a­py as FDA in­ves­ti­gates de­liv­ery de­vice

6 years ago
Cell/Gene Tx
FDA+

Bio­gen dou­bles down on biosim­i­lars pact with Sam­sung Bioepis, bag­ging oph­thal­mol­o­gy, an­ti-TNF drugs

6 years ago
Deals

Alzheimer's break­through? Not so fast — ex­perts poke holes in da­ta un­der­ly­ing Chi­na's sur­prise ap­proval

6 years ago
China
In Focus

As­traZeneca sketch­es plans for a $1B ven­ture fund — and it's go­ing to Chi­na

6 years ago
Financing
China

Eli Lil­ly, Boehringer In­gel­heim re­vise pro­lif­ic di­a­betes pact, fir­ing all cylin­ders for block­buster Jar­diance ...

6 years ago
Deals

Unum drops an­oth­er pro­gram for trou­bled PhI ther­a­py, mov­ing its eggs to the sol­id tu­mor bas­ket

6 years ago
R&D

Sino Bio­pharm, Or­biMed back Mer­ck-part­nered Ake­so­bio's bet on made-in-Chi­na an­ti­bod­ies

6 years ago
Financing
China

Alzheimer's stun­ner: Chi­nese biotech wins OK for a new drug on pos­i­tive da­ta — and they have some high-pro­file ...

6 years ago
China
FDA+

Vik Ba­jaj un­veils Fore­site's new in­cu­ba­tor, look­ing to hatch fu­ture gi­ants cross­ing tech and health­care

6 years ago
Startups

No­var­tis' $111M bet on IL-17C drug turns sour — but Mor­phoSys, Gala­pa­gos will ex­plore op­tions

6 years ago
Deals
R&D

A deal-hun­gry Ver­tex ush­ers in three more gene edit­ing pro­grams as it clos­es out har­bin­ger CRISPR deal

6 years ago
Deals

As­cen­t­age soars dur­ing its first day on the Hong Kong ex­change, fol­low­ing $53M de­but

6 years ago
Financing
China

Div­ing deep in­to AMD, Yale re­searchers pin­point cell types drug de­vel­op­ers should pay spe­cial at­ten­tion to

6 years ago
Discovery

A tale of two IPOs (plus one): Ca­balet­ta prices well be­low range for $75M while Phath­om bags $182M

6 years ago
Financing

Am­gen com­mits to low-cost Repatha; AZTher­a­pies bags Smith Ther­a­peu­tic­s' CAR-Treg tech for neu­roin­flam­ma­tion

6 years ago
R&D
News Briefing

As clock ticks, Trump will nom­i­nate Stephen Hahn as FDA com­mis­sion­er next week — re­port

6 years ago
People
FDA+

Glax­o­SmithK­line cel­e­brates an­oth­er Ze­ju­la win in late-line ovar­i­an can­cer — and an FDA nod for the HRD bio­mark­er

6 years ago
Pharma
First page Previous page 87888990919293 Next page Last page
A service from the Financial Times